Equity Research Diagnostics & Research

Should You Buy Thermo Fisher Scientific Inc Stock in 2026?

By CirclFi Research Team · · 12/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Thermo Fisher Scientific Inc (TMO) scores a robust 8.7/10 on our 32-signal Quality of Company framework. At the current market price of $532.48 and a $197.9B market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.

The short answer: 1 of 12 CirclFi valuation models project upside for Thermo Fisher Scientific Inc (TMO) at $532.48 — the model consensus leans bearish, with a Quality Score of 8.7/10 and Value-Trap risk of 8/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 11 of 12 models suggest overvaluation — majority bearish
  • Quality Score: 8.7/10 — Excellent — top-tier fundamentals
  • Value Trap Risk: 8/100 — Minimal — healthy fundamentals
  • Fair Value Range: $90.17 – $543.24 (502% spread)

Bullish Models

1 / 12

Bearish Models

11 / 12

Quality Score

8.7 /10

Excellent — top-tier fundamentals

Value Trap Risk

8 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

12 /13
Active Models

Avg. confidence: 49%

Investment Thesis

The Bull Case

Target: $543.24 (+2.0% upside)

  • According to the CirclFi Quality of Company (QOC) framework, Thermo Fisher Scientific Inc's rating of 8.7/10 signals strong fundamentals — high-quality businesses tend to compound value more reliably.
  • Industry tailwind: therapeutic area leadership could provide meaningful support for Thermo Fisher Scientific Inc's revenue and margin trajectory in the Diagnostics & Research space.
  • Scale advantage: as a $197.9B large-cap company, Thermo Fisher Scientific Inc benefits from economies of scale, institutional investor demand, and index inclusion that smaller competitors lack.

The Bear Case

Target: $90.17 (-83.1%)

  • According to the CirclFi Deep Alpha Valuation Engine, the EROIC Spread model sees the stock as overvalued with a fair value of $90.17 (-83.1%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +85.1% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
  • Industry headwind: drug pricing legislation represents a meaningful risk for Thermo Fisher Scientific Inc and its Diagnostics & Research peers.

Peer Benchmarking

A Agilent Technologies
10.0
IDXX IDEXX Laboratories,
10.0
MEDP Medpace Holdings, In
10.0
MTD Mettler-Toledo Inter
9.2
CSTL Castle Biosciences,
9.2

Valuation Divergence

Spread

502%

Fair Value Range

$90.17 – $543.24

A 502% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

PWERM

$543.24 (+2.0%)

Most Bearish

EROIC

$90.17 (-83.1%)

Key Risk Factors

Model Disagreement

502% spread signals high variance in projections.

Bearish Consensus

11/12 models suggest overvaluation.

Macro/Sector Risk

Diagnostics & Research headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View TMO Data Page →

The Bottom Line

Our valuation engine sends a clear cautionary signal on Thermo Fisher Scientific Inc at $532.48. 11/12 models flag overvaluation, composite fair value sits at $294.24 (-44.7%), and the risk-reward profile appears unfavorable. Quality at 8.7/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Thermo Fisher Scientific Inc's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy TMO stock right now?

Based on CirclFi's multi-model analysis, 1 of 12 models see upside for TMO at $532.48. The models are divided, which means the investment case depends heavily on your assumptions about Thermo Fisher Scientific Inc's future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Thermo Fisher Scientific Inc?

Key risks include: wide model disagreement (502% spread), signaling high uncertainty; general market and sector-specific risks affecting Diagnostics & Research companies. Always diversify and consult a financial advisor.

How does TMO compare to its competitors?

Among Diagnostics & Research peers, TMO holds a Quality Score of 8.7/10. Comparable companies include A (QOC 10.0), IDXX (QOC 10.0), MEDP (QOC 10.0). The relative ranking helps investors identify whether TMO offers better fundamental quality than alternatives in the same sector.

Is TMO a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. TMO's Quality Score of 8.7/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy TMO at?

CirclFi does not provide target buy prices or price alerts. However, our 12 active models produce fair value estimates ranging from $90.17 to $543.24. At $532.48, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for TMO.

View TMO Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →